No­vo Nordisk paus­es ad cam­paign for obe­si­ty drug We­govy amid un­prece­dent­ed de­mand

2 weeks ago
Pharma
Marketing

Vir en­lists J&J vet to run busi­ness de­vel­op­ment; Gilead finds Kite suc­ces­sor to Christi Shaw

3 weeks ago
Peer Review

Am­gen can close Hori­zon deal by Sep­tem­ber if no rul­ing from courts on FTC suit

3 weeks ago
Pharma
Law

Ex­clu­sive: Cell and gene ther­a­py biotech cre­ator Re­play plucks Al­lo­gene CMO Arun Bal­aku­maran to lead clin­i­cal tri­als

3 weeks ago
People
Cell/Gene Tx

Pri­or­i­ty re­view for Take­da’s ul­tra-rare blood clot ERT; FDA to give an­oth­er look at Arde­lyx’s CKD drug

3 weeks ago
News Briefing
FDA+

Ex-FDA neu­ro chief Bil­ly Dunn is tak­ing a spin through the re­volv­ing door with bio­phar­ma — and that's a prob­lem

3 weeks ago
Bioregnum
FDA+

Roche touts PhII win for BTK in­hibitor in mul­ti­ple scle­ro­sis as PhI­II show­down with Sanofi, Mer­ck KGaA, No­var­tis looms

3 weeks ago
R&D

BioX­cel touts healthy vol­un­teer da­ta for neu­ro ther­a­py; Io­n­is, Chi­nook part­ner on rare kid­ney dis­ease

3 weeks ago
News Briefing

$97M gene ther­a­py con­sor­tium aims to give com­pa­nies and rare dis­ease fam­i­lies a ‘north star’

3 weeks ago
R&D
FDA+

Pe­ter Hecht has a new syn­di­cate, $81M in back­ing and a fresh shot at glo­ry as his last start-up sput­ters out

3 weeks ago
R&D

Der­ma­van­t's Vta­ma works again in eczema as Roivant sub­sidiary seeks la­bel ex­pan­sion next year

3 weeks ago
R&D

Mod­er­na goes af­ter Al­ny­lam, fil­ing coun­ter­claims in Spike­vax patent suit

3 weeks ago
Pharma
Law

Still un­der clin­i­cal hold, Ful­crum locks in sea­soned com­mer­cial leader as CEO

3 weeks ago
People
R&D

Verve names sec­ond PC­SK9 can­di­date; Ex­sci­en­tia picks an­oth­er AI-cre­at­ed mol­e­cule for clin­ic

3 weeks ago
News Briefing

Fu­sion and Cyteir re­fo­cus pipelines; Nona Bio­sciences col­lab­o­rat­ing with Phar­maEssen­tia

3 weeks ago
News Briefing

Astel­las pres­i­dent jumps to a new Fron­tier; Gri­fols chair­man named CEO, break­ing fam­i­ly tra­di­tion

4 weeks ago
Peer Review

Ole­ma gives small up­date to breast can­cer drug at cen­ter of lay­offs, 2021 da­ta leak

4 weeks ago
R&D

Deer­field launch­es ra­dio­ther­a­py com­pa­ny; UCLA gene edit­ing spin­out se­cures funds

4 weeks ago
News Briefing

Ex­clu­sive: Af­ter win­ning le­gal bat­tle, for­mer Phase­Bio in­vestor finds US buy­er for its PhI­II drug to re­verse Bril­in­ta

4 weeks ago
Deals

The E100: Ex­tend­ing run­ways, dump­ing drugs, fac­tor­ing in a bank­ing cri­sis and grap­pling with the IRA — there's a lot for biotech ex­ecs to deal with

4 weeks ago
Bioregnum
Special

FDA ad­comm votes unan­i­mous­ly in fa­vor of ben­e­fit-risk pro­file of over-the-counter con­tra­cep­tive Opill

4 weeks ago
Pharma

CRO deal space con­tin­ues to buzz as Gen­e­sis Drug Dis­cov­ery buys JSS Med­ical Re­search

4 weeks ago
Deals
Outsourcing

Chiesi, Pro­tal­ix's Fab­ry dis­ease treat­ment is ap­proved as Elfab­rio joins Fab­razyme, Galafold

4 weeks ago
FDA+

FDA lifts par­tial hold on Salarius' Ew­ing sar­co­ma drug tri­al

4 weeks ago
R&D
FDA+
First page Previous page 12345 Next page Last page
A service from the Financial Times